Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 6.7% – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded up 6.7% on Friday . The stock traded as high as $37.83 and last traded at $37.8790. 210,198 shares were traded during trading, a decline of 51% from the average session volume of 433,346 shares. The stock had previously closed at $35.50.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of research analyst reports. Truist Financial began coverage on Dianthus Therapeutics in a research note on Tuesday, October 14th. They issued a “buy” rating and a $56.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, October 8th. Raymond James Financial reaffirmed an “outperform” rating and set a $63.00 price target (up previously from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Stifel Nicolaus lifted their price target on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, HC Wainwright boosted their price objective on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Monday. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.43.

Dianthus Therapeutics Stock Up 11.3%

The company has a 50 day simple moving average of $35.66 and a 200-day simple moving average of $25.48. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -11.26 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.58 million. On average, equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 8.15% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DNTH. Integral Health Asset Management LLC acquired a new stake in Dianthus Therapeutics in the 3rd quarter valued at approximately $5,902,000. Wellington Management Group LLP increased its holdings in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares during the period. Glenmede Investment Management LP bought a new stake in shares of Dianthus Therapeutics during the third quarter valued at about $213,000. Marshall Wace LLP acquired a new stake in Dianthus Therapeutics in the third quarter worth about $22,545,000. Finally, Sei Investments Co. bought a new position in Dianthus Therapeutics in the 3rd quarter valued at about $562,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.